• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Cybin Inc. - Common Stock (NQ:HELP)

    11.35 -0.83 (-6.81%)
    Streaming Delayed Price Updated: 1:16 PM EDT, Aug 31, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 767,422
    Open 11.97
    Bid (Size) 11.33 (1,000)
    Ask (Size) 11.36 (300)
    Prev. Close 12.18
    Today's Range 11.27 - 12.19
    52wk Range 3.760 - 14.35
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    InvestorNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Appoints Regina Donohue Chief People Officer and Suresh Durgam to Scientific Advisory Board
    Via Investor Brand Network
    News headline image
    Helus Pharma Appoints Regina Donohue as Chief People Officer and Suresh Durgam, M.D., to its Scientific Advisory Board
    From Helus Pharma
    Via GlobeNewswire

    Performance

    YTD
    +46.8%
    +46.8%
    1 Month
    +45.1%
    +45.1%
    3 Month
    +142.0%
    +142.0%
    6 Month
    +49.1%
    +49.1%
    1 Year
    +46.8%
    +46.8%

    More News

    Read More
    TinyGemsBreaks – Helus Pharma (TM) (NASDAQ: HELP) (Cboe CA: HELP) Advances HLP003 Phase 3 Program, Targets Q4 2026 Topline Data
    Via Investor Brand Network
    News headline image
    Helus Pharma Reports First Quarter Fiscal 2027 Financial Results and Recent Business Highlights
    From Helus Pharma
    Via GlobeNewswire
    News headline image
    Cybin Conference: Helus CEO Eyes Q4 Phase III Depression Data for HLP003 ↗
    Via MarketBeat
    Topics Intellectual Property
    MissionIRNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) CEO to Participate in Canaccord Genuity Growth Conference
    Via Investor Brand Network
    News headline image
    Helus Pharma to Participate at the Canaccord Genuity 46th Annual Growth Conference in Boston
    From Helus Pharma
    Via GlobeNewswire
    News headline image
    A CEO With a Proven Track Record of Success in Growing and Scaling Biopharmaceutical Companies Just Appointed CEO at a Clinical-Stage Biotech, Months Before Its Pivotal Phase 3 Readout
    From USA News Group
    Via GlobeNewswire
    NetworkNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Appoints Michael Halstead as CEO
    Via Investor Brand Network
    News headline image
    Helus Pharma Appoints Michael Halstead as Chief Executive Officer
    From Helus Pharma
    Via GlobeNewswire
    BioMedNewsBreaks — Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Completes Enrollment in Phase 3 Depression Study
    Via Investor Brand Network
    Topics Intellectual Property
    News headline image
    Billions Flow Into Next-Generation Depression Treatments as Pharma Innovation Accelerates
    Via FinancialNewsMedia
    Topics Artificial Intelligence
    News headline image
    Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule
    Via FinancialNewsMedia
    News headline image
    Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule
    From Helus Pharma
    Via GlobeNewswire
    News headline image
    Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
    Via FinancialNewsMedia
    News headline image
    Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
    From MarketNewsUpdates.com
    Via GlobeNewswire
    NetworkNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Reports Fiscal 2026 Results, Highlights Phase 3 Progress
    Via Investor Brand Network
    News headline image
    Helus Pharma Reports Recent Business Highlights and Fiscal Year 2026 Financial Results
    From Helus Pharma
    Via GlobeNewswire
    MissionIRNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Closes $50 Million Public Offering
    Via Investor Brand Network
    News headline image
    Helus Pharma™ Announces Closing of US$50 Million Underwritten Offering
    From Helus Pharma
    Via GlobeNewswire
    InvestorNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Prices $50 Million Public Offering
    Via Investor Brand Network
    BioMedNewsBreaks — Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Surpasses 86% Enrollment in Phase 3 APPROACH Trial
    Via Investor Brand Network
    News headline image
    FNM News Break: Helus Pharma Provides Update on APPROACH Phase 3 Trial Enrollment Progress
    Via FinancialNewsMedia
    News headline image
    Helus Pharma™ Announces US$50 Million Underwritten Offering
    From Helus Pharma
    Via GlobeNewswire
    News headline image
    Helus Pharma Provides Update on APPROACH Phase 3 Trial Enrollment Progress
    From Helus Pharma
    Via GlobeNewswire

    Frequently Asked Questions

    Is Cybin Inc. - Common Stock publicly traded?
    Yes, Cybin Inc. - Common Stock is publicly traded.
    What exchange does Cybin Inc. - Common Stock trade on?
    Cybin Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Cybin Inc. - Common Stock?
    The ticker symbol for Cybin Inc. - Common Stock is HELP on the Nasdaq Stock Market
    What is the current price of Cybin Inc. - Common Stock?
    The current price of Cybin Inc. - Common Stock is 11.35
    When was Cybin Inc. - Common Stock last traded?
    The last trade of Cybin Inc. - Common Stock was at 08/31/26 01:16 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.